Cargando…

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer

The relationship between overall survival (OS) and disease progression end points has been demonstrated in colorectal, colon, and non-small cell lung cancers. We assessed the association between OS and time-to-progression (TTP) or progression-free survival (PFS) in metastatic breast cancer (MBC) stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sherrill, B, Amonkar, M, Wu, Y, Hirst, C, Stein, S, Walker, M, Cuzick, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584937/ https://www.ncbi.nlm.nih.gov/pubmed/19002178 http://dx.doi.org/10.1038/sj.bjc.6604759

Ejemplares similares

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
por: Delea, T E, et al.
Publicado: (2012)

Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia
por: Oyekunle, Anthony A., et al.
Publicado: (2015)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
por: Latimer, Nicholas R., et al.
Publicado: (2016)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
por: Khoja, Leila, et al.
Publicado: (2016)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
por: Aft, R L, et al.
Publicado: (2012)

Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors
por: Tas, Faruk
Publicado: (2012)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer
por: Bertorelle, R, et al.
Publicado: (2013)

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
por: Chavarri-Guerra, Y, et al.
Publicado: (2014)

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
por: Golan, T, et al.
Publicado: (2014)

Nomogram prediction for overall survival of patients diagnosed with cervical cancer
por: Polterauer, S, et al.
Publicado: (2012)

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
por: Mathew, P, et al.
Publicado: (2008)

Factors influencing overall survival rates for patients with pineocytoma
por: Clark, Aaron J., et al.
Publicado: (2010)

Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
por: Chen, Tom Wei-Wu, et al.
Publicado: (2020)

Determination of TGFβ1 protein level in human primary breast cancers and its relationship with survival
por: Desruisseau, S, et al.
Publicado: (2006)

Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010)

C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk
por: Eklund, C M, et al.
Publicado: (2009)

Incidentally Found Prostate Cancer and Influence on Overall Survival after Radical Cystoprostatectomy
por: Sruogis, Algimantas, et al.
Publicado: (2012)

A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
por: Wang, J, et al.
Publicado: (2011)

Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort
por: Díaz-Casas, Sandra Esperanza, et al.
Publicado: (2022)

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer
por: van de Laar, R, et al.
Publicado: (2014)

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
por: Golan, Talia, et al.
Publicado: (2017)

Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis
por: Roka, F, et al.
Publicado: (2005)

The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma
por: Klingenschmid, Julia, et al.
Publicado: (2022)

High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
por: Pichler, M, et al.
Publicado: (2013)

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
por: Lobbezoo, D J A, et al.
Publicado: (2015)

Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy
por: Baulies, S, et al.
Publicado: (2015)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)
por: Vernerey, Dewi, et al.
Publicado: (2016)

The association of waiting times from diagnosis to surgery with survival in women with localised breast cancer in England
por: Redaniel, M T, et al.
Publicado: (2013)

Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis
por: Ishioka, J, et al.
Publicado: (2012)

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival
por: Parker, C, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_2dpk628qvqvunvvbd0de9ffc7d